Skip to content
NewA calmer, faster ZeroHour

Isomorphic Labs raises $5 billion in second mega-round in six months

Original title: Isomorphic Labs raises $5 billion in its second mega-round within six months

The Decoderby Maximilian Schreiner ()1 min read1
Part of a story covered by 2 sourcesIsomorphic Labs raises $5 billion to move drugs toward trialsMerged summary & timeline
AI summary · x-ai/grok-4.7Summaries by Vani AI

The May 2026 round was $2.1 billion; funds target IsoDDE and clinical trials, with no approved drug yet.

Alphabet’s drug-discovery company Isomorphic Labs raised $5 billion, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz, Alphabet and existing investors. The company says the money will advance its IsoDDE platform, which it says goes beyond AlphaFold 3 on binding and docking, and move its pipeline toward trials. It works with Novartis, Eli Lilly and Johnson & Johnson. Demis Hassabis leads the firm after leaving day-to-day Google DeepMind leadership in August 2026.

Unconfirmed: Claims that IsoDDE predicts binding and docking better than AlphaFold 3 are the company’s.

Key facts
  • Isomorphic Labs was founded in 2021 and is led by Demis Hassabis.
  • DeepMind’s original AlphaFold team was disbanded in July 2026.
  • Nearly a quarter of that team left DeepMind; many joined Isomorphic or other projects.
  • DeepMind shipped AlphaGenome 2 in early November 2026.
Explain this AI news with Vani AIWhat was announced, what is new and why it matters, in a new chat

From the original article

1 min read at the-decoder.com

Isomorphic Labs has raised $5 billion, just six months after a $2. 1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials.

The Decoder

By Maximilian Schreiner · the-decoder.com

Read the full article at The Decoder

A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.